This database contains 8 studies, archived under the term: "alleles"
Effects of hormone therapy on depressive symptoms and cognitive functions in women with Alzheimer disease: a 12 month randomized, double-blind, placebo-controlled study of low-dose estradiol and norethisterone
Valen-Sendstad, Arnhild,
Engedal, Knut,
Stray-Pedersen, Babill,
Strobel, Carsten,
Barnett, Liv,
Meyer, Nicolay,
Nurminemi, Minna
Objective: To elucidate the effects of low-dose 17beta-estradiol and norethisterone (hormone therapy [HT]) versus placebo in women with Alzheimer Disease (AD) on cognition, depressive symptoms, and activities of daily living.; Design: A 12-month randomized, double-blind, placebo-controlled study, stratified by apolipoprotein E (ApoE) genotype (with versus without the epsilon4 allele), duration of education (< or =9 […]
Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer’s disease
Zhong, Yuan,
Zheng, Xueli,
Miao, Ya,
Wan, Lili,
Yan, Hong,
Wang, Beiyun
Background: The aim of this study was to evaluate the effect of CYP2D6*10 and APOE polymorphisms on both steady-state plasma concentrations (Cp) and clinical response of donepezil in patients with mild-to-moderate Alzheimer’s disease (AD).; Methods: A total of 110 Chinese AD patients participated in this study. Patients were treated with 5 to 10 mg of […]
Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms
Dombrovski, Alexandre Y.,
Mulsant, Benoit H.,
Ferrell, Robert E.,
Lotrich, Francis E.,
Rosen, Jules I.,
Wallace, Meredith,
Houck, Patricia R.,
Mazumdar, Sati,
Pollock, Bruce G.
The risk/benefit ratio of pharmacotherapy for behavioral symptoms of dementia is questionable: second-generation antipsychotics are poorly tolerated, and the efficacy of alternative treatments, for example, selective serotonin-reuptake inhibitors (SSRIs), is uncertain. Biomarkers of treatment response may improve this risk/benefit ratio. The length polymorphism of the serotonin transporter promoter gene (5-HTTLPR/SLC6A4) may moderate tolerability of SSRIs […]
Rosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: results from a randomized, double-blind, placebo-controlled phase III study
Gold, Michael,
Alderton, Claire,
Zvartau-Hind, Marina,
Egginton, Sally,
Saunders, Ann M.,
Irizarry, Michael,
Craft, Suzanne,
Landreth, Gary,
Linnamägi, Ulla,
Sawchak, Sharon
Background/aims: A phase II study of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone extended release (RSG XR) in mild-to-moderate Alzheimer’s disease (AD) detected a treatment benefit to cognition in apolipoprotein E(APOE)-ε4-negative subjects. The current phase III study with prospective stratification by APOE genotype was conducted to confirm the efficacy and safety of RSG XR in mild-to-moderate […]
Accelerated cell aging in female APOE-ε4 carriers: implications for hormone therapy use
Jacobs, Emily G.,
Kroenke, Candyce,
Lin, Jue,
Epel, Elissa S.,
Kenna, Heather A.,
Blackburn, Elizabeth H.,
Rasgon, Natalie L.
Apolipoprotein-ε4 (APOE-ε4) is a major genetic risk factor for cognitive decline, Alzheimer’s disease (AD) and early mortality. An accelerated rate of biological aging could contribute to this increased risk. Here, we determined whether APOE-ε4 status impacts leukocyte telomere length (TL) and the rate of cellular senescence in healthy mid-life women and, further, whether hormone replacement […]
Mental and physical activities delay cognitive decline in older persons with dementia
Cheng, Sheung-Tak,
Chow, Pizza K.,
Song, You-Qiang,
Yu, Edwin C.S.,
Chan, Alfred C.M.,
Lee, Tatia M.C.,
Lam, John H.M.
Objectives: To examine the effects of cognitive stimulation (mahjong) and physical exercise (tai chi [TC]) on cognitive performance in persons with dementia.; Design: Cluster-randomized open-label controlled design.; Setting: Nursing homes.; Participants: One hundred ten residents, most of whom were cholinesterase-inhibitor naive. Inclusion criteria were Mini-Mental State Examination (MMSE) = 10-24 and suffering from at least very mild […]
The effect of midlife physical activity on cognitive function among older adults: AGES–Reykjavik Study
Chang, M.,
Jonsson, P. V.,
Snaedal, J.,
Bjornsson, S.,
Saczynski, J. S.,
Aspelund, T.,
Eiriksdottir, G.,
Jonsdottir, M. K.,
Lopez, O. L.,
Harris, T. B.,
Gudnason, V.,
Launer, L. J.
Background: There are few studies on the long-term associations of physical activity (PA) to cognition. Here, we examine the association of midlife PA to late-life cognitive function and dementia.; Methods: The sample consisted of a population-based cohort of men and women (born in 1907-1935) participating in the Age Gene/Environment Susceptibility-Reykjavik Study. The interval between the […]